Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major
cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of …

Dabigatran is approved for stroke risk reduction in patients with nonvalvular atrial fibrillation
(NVAF). Data from diverse clinical practice settings will help establish whether the risk …

NR4A2 is a nuclear receptor and a transcription factor, with distinctive physiological
features. In the cell nuclei of the central nervous system, it is widely expressed and identified …

About 1.4 British million people are at risk of strokes due to non-valvular atrial fibrillation (AF)
necessitating long-term anticoagulation. The vitamin K antagonist, warfarin, has a long half …

Abstract Essentials• A State of the Art lecture “Clotting factors and atherothrombosis” was
presented at the ISTH congress 2017.• Coagulation proteins are not only involved in …

Background: Evidence is conflicting as to the efficacy of direct oral anticoagulation (DOAC)
and vitamin K antagonist (VKA) for prevention of myocardial infarction (MI). Objectives: This …

Background: The optimal treatment strategy when combining antiplatelets with oral
anticoagulants in patients with atrial fibrillation (AF) and myocardial infarction (MI) or …

Even 10 years after the first appearance in the literature of articles reporting on the
management of patients on oral anticoagulation (OAC) undergoing percutaneous coronary …

Aim Direct oral anticoagulants (DOACs) have shown noninferiority to warfarin for stroke
prevention in nonvalvular atrial fibrillation (AF) and a more promising safety profile …